Last reviewed · How we verify
Long Course Adjuvant Chemotherapy
Long course adjuvant chemotherapy delivers extended cycles of cytotoxic chemotherapy after primary cancer treatment to eliminate residual disease and reduce recurrence risk.
Long course adjuvant chemotherapy delivers extended cycles of cytotoxic chemotherapy after primary cancer treatment to eliminate residual disease and reduce recurrence risk. Used for Adjuvant treatment of resected colorectal cancer or other solid tumors at high risk of recurrence.
At a glance
| Generic name | Long Course Adjuvant Chemotherapy |
|---|---|
| Sponsor | Trans Tasman Radiation Oncology Group |
| Drug class | Chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Adjuvant chemotherapy is administered following surgery or primary treatment to target micrometastatic disease that may not be clinically detectable. Long course regimens extend the duration of treatment beyond standard protocols, typically involving multiple cycles of chemotherapy drugs designed to maximize cell kill while the patient's performance status allows. This approach aims to improve disease-free and overall survival in high-risk patients.
Approved indications
- Adjuvant treatment of resected colorectal cancer or other solid tumors at high risk of recurrence
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Diarrhea
- Peripheral neuropathy
- Fatigue
Key clinical trials
- Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION) (PHASE3)
- XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients (PHASE2)
- Efficacy and Safety of Conventional Neoadjuvant Therapy Versus Total Neoadjuvant Therapy in Older Patients With Locally Advanced Rectal Cancer (NA)
- Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) (PHASE2)
- Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial (PHASE3)
- Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer (PHASE4)
- MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer (PHASE2)
- Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: